Key result
Daily subcutaneous injections of 20K-hGH in obese mice significantly reduced relative fat pad and whole body lipids by inhibiting LPL activity and stimulating lipolysis.
Why the study?
Does 20K-hGH reduce body fat and alter lipolysis and LPL activity in obese KV-A(y) mice?
Does 20K-hGH reduce body fat and alter lipolysis and LPL activity in obese KV-A(y) mice?
In a preclinical model, 20K-hGH reduces body fat by inhibiting lipoprotein lipase activity and stimulating lipolysis.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for 20K-hGH in obesity; leaves open translation to human trials.
AIM: The aim of this study was to estimate the lipolytic activity of the human growth hormone variant, 20-kD human growth hormone (20K-hGH). METHODS: Obese KV-A(y) mice were given daily subcutaneous injections of 20K-hGH (0.25, 0.5, 1.0 mg/kg), 22K-hGH (0.25 mg/kg) or saline as a control for 2 weeks. Body composition (fat, water and protein), lipolysis and lipoprotein lipase (LPL) activity were measured 24 h after the final injection. RESULTS: Both growth hormone isoforms significantly reduced relative fat pad and whole body lipids. In addition, 20K-hGH produced an inhibition of LPL activity in adipose tissue and stimulated lipolysis in adipocytes. CONCLUSION: These data strongly suggest that inhibition of LPL activity in adipose tissue and stimulation of lipolysis in adipocytes by 20K-hGH treatment reduce adipose tissue mass, resulting in body fat reduction.
No takes yet. Share an insight, caveat, or question.
Takahashi et al. (2002) studied Obesity. 20-kD human growth hormone (20K-hGH) vs. 22K-hGH (0.25 mg/kg) or saline was evaluated on Body composition (fat, water and protein), lipolysis and lipoprotein lipase (LPL) activity. Daily subcutaneous injections of 20K-hGH in obese mice significantly reduced relative fat pad and whole body lipids by inhibiting LPL activity and stimulating lipolysis.
Synapse has enriched 10 related papers. Consider them for comparative context: